Sparsentan (Filspari) in IgA Nephropathy: Why Protein in the Urine Fell in Both Diseases but the Indication Came in Only One
Ukraine, Dnepr, st. 25 Sicheslavskaya Brigade (Rybinskaya St.), 119 ‑ 120
Ukraine, Dnepr, st. 25 Sicheslavskaya Brigade (Rybinskaya St.), 119 ‑ 120

Sparsentan (Filspari) in IgA Nephropathy: Why Protein in the Urine Fell in Both Diseases but the Indication Came in Only One

A guide to sparsentan (Filspari): how dual blockade of endothelin and angiotensin protects the kidney filter, the PROTECT numbers in IgA nephropathy — urine protein 40% lower than on irbesartan and a slower loss of kidney function — the DUPLEX data in FSGS, how it is used and who should see a doctor first.

Sparsentan (Filspari) in IgA Nephropathy: Why Protein in the Urine Fell in Both Diseases but the Indication Came in Only One
Sparsentan (Filspari) is the first dual endothelin and angiotensin blocker to gain an indication in IgA nephropathy. In the PROTECT trial, at week 110 urine protein was 40% lower than on the ordinary ARB irbesartan, and kidney function was lost more slowly. Here is how dual blockade works, what PROTECT and DUPLEX showed, how the drug is used and who should see a doctor first.

Key Points

Sparsentan (Filspari) is a tablet that blocks two targets with one molecule: the endothelin A receptor and the angiotensin II type 1 receptor. It is the first dual-blockade agent to gain an indication in IgA nephropathy — the most common glomerular disease in the world.

WhereHow it helpsWhat human studies showed
Primary IgA nephropathy in adults at high risk of progressionless protein in the urine than on an ARBPROTECT (Lancet, 2023), 404 patients: at week 110 urine protein 40% lower than on irbesartan (−42.8% versus −4.4%) [1]
Kidney function in IgA nephropathykidney function is lost more slowlyin the same trial the rate of eGFR decline was −2.7 versus −3.8 mL/min/1.73 m² per year (difference 1.1; p=0.037) [1]

How It Helps

What Breaks in IgA Nephropathy

Immunoglobulin A normally guards the mucous membranes. In this disease it is produced with a structural defect: part of the molecule lacks the sugars it should carry. The body reads such immunoglobulin as foreign and raises antibodies against it.

The resulting complexes settle in the glomeruli — the microscopic filters through which blood passes. Chronic inflammation begins, the filter is damaged, and protein that should stay in the blood escapes into the urine.

The key cell of that filter is the podocyte. It wraps around the capillary with foot processes, leaving slits of a strictly defined width between them. Damage to the podocyte means the slits widen and the barrier stops holding protein back. A full account of how the filter is built is in the separate guide on the podocyte.

Two Targets in One Molecule

For decades kidney protection has been built on suppressing the angiotensin system — the job of ACE inhibitors and ARBs. This lowers pressure inside the glomerulus and reduces protein loss.

But there is a second route of damage: endothelin, the most powerful vasoconstrictor peptide known. In glomerular disease it amplifies inflammation and damages podocytes directly.

Sparsentan closes both routes with one molecule: one part binds the angiotensin receptor, the other the endothelin A receptor.

ARB (e.g. irbesartan)Sparsentan
Angiotensin II receptorBlockedBlocked
Endothelin A receptorNoBlocked
Number of drugsOne pathway, one drugTwo pathways, one drug
Restricted programme in the USNoYes (REMS)

What the Trials Showed

Sparsentan was tested in two large trials — in IgA nephropathy (PROTECT [1]) and in focal segmental glomerulosclerosis (FSGS; DUPLEX [2]). In both the comparator was irbesartan, an ordinary ARB rather than placebo: an honest bar.

Protein in the urine is a marker. It is convenient: quick to measure, responsive to treatment within weeks rather than years. The goal is something else — preserving kidney function and postponing dialysis — and that takes years of follow-up to show.

In IgA nephropathy sparsentan delivered both results: urine protein fell and kidney function began to be lost more slowly. That is why the regulator first granted accelerated approval on proteinuria and full approval eighteen months later, once the two-year eGFR data arrived.

How to Take It

ParameterDetail
FormulationTablets
WhoAdults with primary IgA nephropathy at high risk of progression
Starting therapyAfter biopsy and assessment of kidney function, by nephrologist decision
MonitoringLiver enzymes, potassium, blood pressure, kidney function
CompatibilityNot combined with ACE inhibitors, ARBs or other endothelin antagonists

Sparsentan does not replace the rest of treatment: blood pressure control, salt restriction and stopping smoking remain part of kidney care.

Who Should See a Doctor First

The decision belongs to a nephrologist: biopsy, assessment of kidney function, blood pressure control and baseline liver status are all required. Self-selection is out of the question here.

Precautions

▸ Liver. The drug can cause hepatic injury. Enzymes are checked before starting and regularly during treatment.
▸ Pregnancy. Acting on both the angiotensin system and endothelin is toxic to the fetus. Pregnancy is excluded before the start and reliably prevented during therapy.
▸ Restricted programme. Because of these two risks the drug is distributed in the US through REMS: an ordinary prescription is not enough — prescriber and pharmacy must both be enrolled.
▸ Blood pressure and potassium. Dual blockade affects blood pressure more than a single ARB; potassium is monitored.

Who It Is Not For

▸ Anyone pregnant or planning pregnancy.
▸ Patients with pre-existing liver disease — decided case by case and requiring monitoring.
▸ Anyone already on an ACE inhibitor or ARB who is not prepared to stop it: these drugs are substituted, not stacked.
▸ Patients with FSGS, under the current indication.

Bottom Line

▸ Dual blockade of endothelin and angiotensin in one molecule is a new way of protecting the kidney filter.
▸ PROTECT: urine protein 40% lower than on irbesartan, and kidney function lost more slowly — which is why the indication in IgA nephropathy was granted.
▸ Treatment under a nephrologist: liver monitoring, excluded pregnancy, a REMS programme in the US.

Treatment can be discussed at a consultation; the drug can be ordered here.

References

1. Rovin BH, et al. Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial. Lancet. 2023;402(10417):2077–2090. PMID 37931634

2. Rheault MN, et al. Sparsentan versus Irbesartan in Focal Segmental Glomerulosclerosis. N Engl J Med. 2023;389(26):2436–2445. PMID 37921461

3. Heerspink HJL, et al. Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial. Lancet. 2023;401(10388):1584–1594. PMID 37015244

4. FILSPARI (sparsentan) — US Prescribing Information, Travere Therapeutics.

Source: Sparsentan (Filspari) in IgA Nephropathy: Why Protein in the Urine Fell in Both Diseases but the Indication Came in Only One — universum.earth. Dr. Pereligyn.

Come back
Request a call back